



Roseweir, A. K. , Halcrow, E. S., Chichilo, S., Powell, A. G.M.T., McMillan, D. C. , Horgan, P. G. and Edwards, J. (2018) ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer. *British Journal of Cancer*, 119, pp. 323-329.(doi:[10.1038/s41416-018-0174-y](https://doi.org/10.1038/s41416-018-0174-y))

This is the author's final accepted version.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<http://eprints.gla.ac.uk/163907/>

Deposited on: 13 June 2018

Enlighten – Research publications by members of the University of Glasgow
<http://eprints.gla.ac.uk>

ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer

Running Title: MAPK pathway in colorectal cancer patients

**Antonia K Roseweir^{1,2}, Elaine S Halcrow², Sergey Chichilo², Arfon GMT Powell³,
Donald C McMillan¹, Paul G Horgan¹, and Joanne Edwards²**

¹ Academic Unit of Surgery, School of Medicine-University of Glasgow, 2nd Floor New Lister Building, Royal Infirmary, Glasgow, UK G4 OSF.

² Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Garscube Estate, Glasgow, UK, G61 1QH.

³ Division of Cancer and Genetics, Cardiff University, UHW Main Building, Heath Park, Cardiff, UK, CF14 4XN.

Corresponding Author: Dr Antonia Roseweir, Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Glasgow, G61 1QH, United Kingdom, 0141 330 8607, antonia.roseweir@glasgow.ac.uk.

ABSTRACT

Background: In colorectal cancer (CRC), BRAF mutations influence tumour progression. In mismatch repair deficient (dMMR) tumours, BRAF mutations are associated with a good prognosis whereas in MMR competent tumours they are detrimental. The differential expression of the downstream MAPK pathway members, which are constitutively activated in BRAF mutant patients, may account for these differences.

Methods: Phosphorylation of ERK, p38MAPK and JNK was assessed by immunohistochemistry utilising CRC tissue microarrays. A discovery cohort (n=187) and a validation cohort (n=801) were analysed for associations with BRAF mutations, clinicopathological characteristics and cancer-specific survival (CSS).

Results: In 801 CRC patients, nuclear ERK phosphorylation (HR 0.65 95% CI 0.48-0.88, p=0.004) and the combined nuclear pERK/p-p38 score (HR 0.61 95% CI 0.45-0.82, p=0.001) independently associated with CSS and were further associated with increased BRAF mutations (p=0.003 and p=0.002). When stratified for BRAF status, only MMR competent patients harbouring the mutation and a strong combined nuclear pERK/p-p38 score (HR 0.49 95% CI 0.27-0.89, p=0.016) demonstrated improved CSS. This improvement in CSS was specific to stage III CRC (HR 0.25 95% CI 0.10-0.64, p=0.002).

Conclusions: MMR competent stage III tumours harbouring BRAF mutations have an improved prognosis when strong nuclear phosphorylation of both ERK and p38MAPK is present.

Keyword: ERK, p38MAPK, BRAF mutations, colorectal cancer, and prognosis.

INTRODUCTION

Colorectal cancer (CRC) is the second most common cause of cancer death in Europe¹. Although survival has improved, this is predominantly a result of better surgical technique and adjuvant/neo-adjuvant therapies. Despite this, 5- year survival remains poor at 60% across all stages of disease². The present TNM-based staging of CRC is suboptimal, given the heterogeneity in survival among patients across the same stage of disease. There is an obvious clinical need to identify characteristics pertaining to both the tumour and the host, which may not only guide prognosis but also novel adjuvant therapies.

BRAF V600E mutations are currently being investigated as a predictive biomarker for selecting patients for EGFR inhibitor treatment³. BRAF mutations exhibit different associations with prognosis dependent on the subset of CRC patients. In sporadic CRC, patients with mismatch repair (MMR) deficient (dMMR) tumours harbouring BRAF mutations have an improved survival. Conversely, in MMR competent (cMMR) patients, BRAF mutations convey a poor prognosis and their prognosis declines further in BRAF mutant metastatic disease⁴. Furthermore, dMMR/BRAF mutant patients have a 5-year survival rate of 65% compared to 46% for cMMR/BRAF mutant patients. The reason for this difference in survival for BRAF mutant patients is still unclear, but may lie in the expression of downstream targets such as extracellular regulated kinase (ERK).

ERK is part of the mitogen-activated protein kinase (MAPK) family along with two other members, p38MAPK and c-Jun-regulated kinase (JNK). All MAPKs are serine-threonine kinase activated by dual phosphorylation. The effects of MAPKs on patient survival in various cancers are varied⁵⁻⁸, with some studies showing a survival advantage and some a detrimental survival effect. Most studies look at the three members in isolation, overlooking potential cross talk between the pathways, which may explain the different associations with

survival. Therefore, the aim of the present study was to assess the effect of phosphorylation of ERK, p38MAPK and JNK alone and in combination on cancer-specific survival in a discovery and validation cohort of CRC patients. The study also assessed associations between the MAPK pathway, BRAF mutations, MMR status, and clinicopathological factors.

METHODS

Patients

Discovery cohort patients (n=272) were identified from retrospectively retrieved routine CRC resections performed within Glasgow Royal Infirmary between 1997 and 2007. This cohort was extended to the validation cohort (n=1030) with the addition of retrospectively identified CRC resections performed in the Western Infirmary and Stobhill Hospital, Glasgow in the same time period. Patients who had undergone a potentially curative resection for stage I-III CRC and were included within previously constructed tissue microarrays (TMAs) were studied. Resections were considered curative based on pre-operative computed tomography and intra-operative findings. Patients who had died within 30 days of surgery were excluded. Ethical approval was obtained from the West of Scotland Research Ethics Committee.

Clinicopathological characteristics

Tumours were staged using the fifth edition of the AJCC/UICC-TNM staging system⁹. Tumour differentiation was graded in accordance with Royal College of Pathologists¹⁰. The presence of venous invasion was assessed using Elastica staining. Differentiation, margin involvement, peritoneal involvement, and necrosis were taken from pathology reports issued following resection. Data on Ki67 was already available for both cohorts using a threshold of 50%. MMR status was assessed as previously described¹¹. Patients were followed up for at least five years and date and cause of death were crosschecked with electronic case records. Cancer-specific survival (CSS) was measured from date of surgery until date of death from CRC.

Assessment of inflammatory responses

Stromal infiltration was assessed using tumour stroma percentage (TSP) as previously described¹². The local inflammatory cell infiltrate was assessed using the Klintrup-Makinen (KM) grade¹³. The Glasgow microenvironment score (GMS) was calculated as previously described¹⁴. Tumor-infiltrating lymphocyte (TIL) counts were established from pathology reports issued following resection. For systemic inflammation, serum C-reactive protein (CRP) and albumin were recorded prospectively and measured within 30 days prior to surgery. The pre-operative systemic inflammatory response was defined using the modified Glasgow prognostic score (mGPS)¹⁵.

Immunohistochemistry

BRAF V600E, phosphorylated ERK1/2 (pERK), phosphorylated p38MAPK (p-p38) and phosphorylated JNK (pJNK) were assessed via immunohistochemistry (Figure S1) in the discovery (n=272) and validation TMA (n=758). Antibody validation was performed with a single band on a western blot and EGF or UV stimulated cell pellet +/- inhibitors. For BRAF V600E antibody was also validated using BRAF WT and BRAF V600E mouse colon tissue (Figure S2).

Sections were dewaxed in histoclear then rehydrated using graded alcohols. Antigen retrieval for pERK was performed in citrate buffer at 96°C for 20 minutes or for BRAF V600E, p-p38, and pJNK using Tris EDTA buffer pH8 under pressure for 5 minutes. Endogenous peroxidase activity was blocked using 3% hydrogen peroxidase. 10% Casein (BRAF V600E), 1.5% horse serum (pERK) or 5% horse serum (p-p38/pJNK) was applied as a blocking solution. TMA sections were incubated overnight at 4°C with primary BRAF V600E (1:200, clone VE1, Spring Biosciences #E1929), pJNK (Thr183/Tyr185, 1:50, cell signalling #4668) or p-p38 (Thr180/Tyr182, 1:100, cell signalling #4511) antibody. Primary pERK (Thr202/Tyr204, 1:200, cell signalling #9101) antibody was incubated for 6 hours at room temperature.

Envision (Dako) was used as a secondary antibody before DAB substrate was added for colour development. Slides were counterstained with haematoxylin and blued with Scott's tap water before being dehydrated through a series of graded alcohols and histoclear. Cover slips were applied using distrene, plasticizer, xylene (DPX).

Scoring

Stained TMA sections were scanned using a Hamamatsu NanoZoomer (Welwyn Garden City, Hertfordshire, UK) at x20 magnification and visualized on Slidepath Digital Image Hub (Leica Biosystems, Milton Keynes, UK). Assessment of BRAF V600E, ERK1/2, JNK and p38MAPK phosphorylation was performed by a single examiner blinded to clinical data at x20 magnification (total magnification x400) using the weighted histoscore. The weighted histoscore was calculated as follows: 0x% not stained + 1x% weakly stained + 2x% moderately stained + 3x% strongly stained. This gave a range of scores from 0 to 300 with cytoplasmic and nuclear staining scored separately. 10% of tumours were co-scored by a co-investigator and the interclass correlation coefficient calculated to be <0.7 for all proteins.

Statistical analysis

Histograms were assessed for each protein and BRAF V600E and pERK histograms determined that negative and positive expression was the appropriate threshold. Receiver operator characteristic (ROC) curves were employed to identify the optimal threshold for low/high expression of p-p38 and pJNK in the discovery cohort and validated using the validation cohort, the following thresholds were identified for each protein: 40 for nuclear p-p38, 10 for cytoplasmic p-p38, 70 for nuclear pJNK, and 145 for cytoplasmic pJNK.

SPSS (version 22) was used for statistical analysis. By using a two-sided $\alpha=0.05$ analysis and assuming a hazard ratio (HR) of 0.65 and a both high prevalence of 40% for the combined

nuclear score, a sample size of >178 patients gave >90% power to detect a survival difference between the both low or one high and both high groups. Pearson's χ^2 test assessed associations between MAPK members, BRAF mutations, and clinicopathological features. Kaplan-Meier curves and log-rank analysis compared CSS. HRs and confidence intervals (CI) were calculated from univariate cox regression survival analysis. Multivariate cox regression survival analysis using a backward conditional elimination model and a significance threshold of $p < 0.05$ was performed to identify independent prognostic biomarkers. The study is reported in line with the REMARK guidelines¹⁶ and significance was set as $p < 0.05$.

RESULTS

For the discovery cohort, a total of 187 patients were studied, and they underwent a potentially curative resection for stage I-III CRC and had a valid score for pERK, p-p38 and pJNK. The patient characteristics for the discovery cohort are shown in Table S1. In brief, 64% were 65 or older and 53% were male. 5% had stage I disease, 49% had stage II disease, and 46% had stage III disease. 38% had right-sided colon cancer, 30% had left-sided colon cancer and 32% had rectal cancer. MMR deficiency was identified in 10% and 20% had the BRAF V600E mutation. 31% received adjuvant chemotherapy. The median follow-up for patients was 11.6yrs (range 7.3-16.0yrs) with 65 cancer deaths and 45 non-cancer deaths.

The association between MAPK phosphorylation and CSS within the cytoplasm or nucleus was investigated in Table 1. p-p38 and pJNK were not associated with CSS at either cellular location. However, phosphorylation of ERK significantly improved CSS within the nucleus (HR 0.61 95% CI 0.38-1.00, $p=0.048$). To assess if analysing the MAPK family in combination would provide any additional power, combined prognostic scores were established as follows: combined pERK/p-p38 score, combined pERK/pJNK score and combined p-p38/pJNK score. For all combined scores, patients were split into two groups; patients with weak activation of both proteins or strong activation of one protein was termed both weak or one strong, and patients with strong activation of both proteins termed both strong. Only the combined nuclear pERK/p-p38 score provided some additional power to improve CSS (HR 0.56 95% CI 0.33-0.95, $p=0.030$, Table 1). Next, to assess if this increased power is relevant, this combined pERK/p-p38 score and pERK alone were taken forward into the validation cohort.

To validate these findings the cohort was extended to an 801 CRC patient validation cohort. CRC patients with a valid score for pERK and p-p38 were included. The characteristics of

this cohort are shown in Table S1. In Brief, 68% were 65 or older and 53% were male. 14% had stage I disease, 48% had stage II disease, and 38% had stage III disease. 41% had right-sided colon cancer, 34% had left-sided colon cancer and 24% had rectal cancer. MMR deficiency was identified in 16% and 21% had the BRAF V600E mutation. The median follow-up for patients was 12.0yrs (range 7.3-16.0yrs) with 235 cancer deaths and 258 non-cancer deaths. As this data was similar to that of the discovery cohort it was deemed appropriate to validate the findings.

The validation cohort was assessed for associations with CSS (Table 2); p-p38 did not associate with CSS at either cellular location. However, pERK was associated with improved CSS within both the nucleus (HR 0.76 95% CI 0.59-0.99, $p=0.037$) and cytoplasm (HR 0.77 95% CI 0.60-0.99, $p=0.047$). When the combined pERK/p-p38 score was assessed, associations with improved CSS were strengthened for both nuclear (HR 0.69 95% CI 0.53-0.90, $p=0.005$) and cytoplasmic localisation (HR 0.68 95% CI 0.51-0.92, $p=0.010$).

pERK and the combined pERK/p-p38 score were then assessed for associations with clinicopathological factors as shown in Table 3. Patients with phosphorylation of nuclear ERK were more likely to have a BRAF V600E mutation ($p=0.003$), be MMR competent ($p=0.010$), and have lower CRP levels ($p=0.030$). Similarly, patients with phosphorylation of cytoplasmic ERK were more likely to have a BRAF V600E mutation ($p=0.009$) and be MMR competent ($p=0.032$). For the combined nuclear pERK/p-p38 score, patients with a both strong score associated with increased BRAF V600E mutations ($p=0.002$). Whereas a both strong score for the combined cytoplasmic pERK/p-p38 score associated with older age ($p=0.039$). No associations with other clinicopathological characteristics or local inflammation were seen for any MAPK members.

As the combined nuclear pERK/p-p38 score associated with increased BRAF mutations as well as pERK alone, firstly associations between nuclear p-p38 and BRAF status were assessed as they are normally within divergent MAPK pathways. High nuclear p-p38 did associate with increase BRAF mutations ($p=0.039$, Table S2) suggesting they do interact. Next, patients were stratified into BRAF wildtype or BRAF mutant and effects on patients CSS assessed (Figure 1). For phosphorylation of nuclear ERK, CSS was only improved in patients with BRAF mutations (HR 0.51 95% CI 0.29-0.90, $p=0.018$, Figure 1A). This effect on CSS was slightly potentiated for the combined nuclear pERK/p-p38 score (HR 0.50 95% CI 0.29-0.88, $p=0.014$, Figure 2B). To further assess BRAF mutant patients, the combined nuclear pERK/p-p38 score was assessed for effects pertaining to MMR status (Figure 2). In MMR competent patients, a both strong combined nuclear pERK/p-p38 score improved CSS (HR 0.49 95% CI 0.27-0.89, $p=0.016$). Whereas in MMR deficient patients, a both strong combined pERK/p-p38 score did not significantly improve patient survival (HR 0.45 95% CI 0.08-2.16, $p=0.285$).

To further investigate the utility of the combined nuclear pERK/p-p38 score within BRAF mutant patients, patients were further stratified for TNM-stage. For MMR competent patients (Figure S3), only BRAF mutant patients with stage III CRC had improved survival with a both strong score (HR 0.25 95% CI 0.10-0.64, $p=0.002$, Figure S3C). No survival advantage was seen for stage I (HR 1.84 95% CI 0.19-17.94, $p=0.593$, Figure S3A) or stage II patients (HR 0.97 95% CI 0.36-2.63, $p=0.952$, Figure S3B). No effect of stage was seen in MMR deficient patients.

pERK and the combine pERK/p-p38 score were then taken forwards into multivariate analysis with common clinicopathological factors (Table 4). Under multivariate analysis for all patients ($n=606$), TNM-stage ($p<0.001$), venous invasion ($p=0.006$), margin involvement

($p=0.032$), peritoneal involvement ($p<0.001$), TSP ($P=0.030$), KM grade ($p=0.030$), TILs ($p=0.002$), mGPS ($p<0.001$), nuclear pERK ($p=0.004$) and the combined nuclear pERK/p-p38 score ($p=0.001$) were independent prognostic factors for CSS. When stratified for MMR competent BRAF mutant patients ($n=136$), venous invasion ($p=0.003$), margin involvement ($p=0.009$), mGPS ($p<0.001$) and nuclear pERK ($p=0.042$) remained independently prognostic. When further stratified for stage III patients ($n=53$), margin involvement ($p=0.029$), mGPS ($p=0.001$) and nuclear pERK ($P<0.001$) remained independent for CSS.

DISCUSSION

The results of the present study suggest that patients with CRC need strong nuclear phosphorylation of both ERK and p38MAPK for a good prognosis. The data shows that this survival improvement is enhanced in MMR competent patients with stage III CRC harbouring BRAF mutations. However, patients with strong activation of only one protein have a poorer survival outcome suggesting that these patients may benefit from a ERK or p38MAPK activation.

ERK has long been associated with malignant transformation in various cancers including CRC, with upstream KRAS/BRAF harbouring driver mutations^{6,8,17}. Therefore, it is interesting that this improvement in patient survival is specific to BRAF mutant tumours, with strong activation of ERK. Previous studies have mainly associated phosphorylation of ERK with reduced survival in patients with CRC^{18,19}, however they assessed ERK in isolation, and therefore differences in the activation of p38MAPK between cohorts may account for the difference in survival effects compared to the present study. p38MAPK is thought to suppress cell proliferation in normal cells but can promote proliferation in certain cancer cells, and this has been linked to activation levels²⁰. This observation is similar to ERK, which has also been shown to adapt its proliferative effects depending on activation levels, with strong activation of ERK causing cell cycle arrest and decreased proliferation⁵. Furthermore, p38MAPK has also been shown to suppress ERK activity, which may be important in BRAF mutant tumours where ERK is hyper-activated²¹. In the current study, patients with BRAF mutant tumours have a 3-fold increase in nuclear ERK phosphorylation compared to BRAF WT tumours (data not shown), supporting the hypothesis that ERK is hyper-activated in BRAF mutant patients. Although p38MAPKs is thought to be a poor prognostic factor in CRC that promotes cancer cell survival²², most research to date has been

restricted to cell lines and mouse models^{23,24}. However, the present tissue data suggests that high levels of phosphorylated p38MAPK promote proliferation potentially by inhibiting ERK activation. Therefore, in patients with high phosphorylation of both nuclear p38MAPK and ERK, p38MAPK may dampen the anti-proliferative effects of ERK to maintain cell proliferation. This is in line with previous literature that suggests proliferation measured by Ki67 is a good prognostic factor in patients with CRC^{25,26}. However, if only ERK phosphorylation is high, then the hyper-activation in BRAF mutant tumours will be uncontrolled and start to suppress the cell cycle leading to decreased proliferation and reduced patient survival.

This was observed when assessing the combined nuclear ERK/p38 score in BRAF mutant patients. In BRAF mutant patients with strong activation of both ERK and p38MAPK, survival is significantly improved. It is interesting to note that in these patients of the 115 patients with strong activation of ERK, 95 patients also had strong activation of p38. This suggests that dual activation is common in BRAF mutant tumours and accounts for why only a slight increase in power is seen between nuclear pERK and the combined pERK/p-p38 score (figure 1). This dual activation protects the patient against the hyper-activation of ERK allowing the tumor to continue to proliferate, which has been previously shown to convey a good prognosis to patients with CRC²⁵. However, when only one MAPK is highly active or both are weak, survival is decreased, which suggests that for a protective influence to ensue, high activation levels of both members are required. When only one member is activated, both proliferation and survival rates are lowered to a similar level to that observed for patients that have low activation of both. This suggests that proliferation needs to be driven by both members for improved patient prognosis. This effect is not seen in BRAF WT patients, suggesting that only when ERK is hyper-activated can it affect the cell cycle inhibiting proliferation, which leads to a worse prognosis for these patients. In BRAF WT

patients the levels of ERK activation never reach the threshold to affect the cell cycle, so the reduction in proliferation and survival is never produced.

As BRAF mutations are commonly associated with MMR deficient patients⁴, we next stratified BRAF mutant patient by MMR status. In patients with MMR competent CRC, similar results were seen with a both strong nuclear ERK/p38 score conveying a survival advantage to the patient, suggesting that this score would be a useful prognostic marker in these patients. To confirm the utility of this prognostic marker across all disease stages of CRC, we next stratified MMR competent BRAF mutant patients by stage, and found that this survival advantage with the nuclear ERK/p38 score was potentiated in patients with stage III CRC. Patients with a both weak/one strong score had significantly poorer survival rates. In contrast, the survival difference previously observed was lost in stage I/II patients. These finding suggest that BRAF mutational analysis should be extended beyond it's current clinical application in metastatic disease to the adjuvant setting to further aid clinicians with patient prognosis.

In conclusion, this is the first study to show a combined survival advantage of ERK and p38MAPK in MMR competent BRAF mutant patients with stage III CRC; confirmation in an independent cohort is needed. One limitation of this study is that it does not cover metastatic disease and therefore further analysis of this combine score in BRAF mutant metastatic patients is also warranted. Overall, these results suggest that patients within the adjuvant setting with MMR competent Stage III CRC should not only be routinely tested for BRAF mutations but should also be further tested for phosphorylation of ERK and p38MAPK to fully stratify prognosis. Furthermore, strong expression of only one of these proteins (ERK or p38MAPK) could be used as a predictive biomarker for clinical trials in BRAF mutant MMR competent CRC patients, establishing the benefit of treatment with an agonist to the other

member (ERK for p38MAPK agonist and p38MAPK for ERK agonist). This approach would assess if this combined MAPK score truly has a prognostic benefit and would help move towards a precision medicine approach for patients with CRC.

ADDITIONAL INFORMATION

Ethics approval - Ethical approval was obtained from the West of Scotland Research Ethics Committee for use of surplus tissue (16WS0207) and was performed in accordance with the Declaration of Helsinki.

Availability of Data and Material – All clinical information is held within a database available from the NHS GGC Safehaven and tissue microarrays are available from the NHS Research Scotland GGC Biorepository.

Conflict of Interest – The authors declare no conflicts of interest.

Funding - The Hugh Fraser Non-Clinical Lecturer in Surgery Fellowship and The Royal College of Physicians and Surgeons of Glasgow Ritchie Trust Fellowship supported this work.

Author Contributions – AKR designed the experiments, performed experiments, analyzed the data, and wrote the manuscript; ESH performed experiments and reviewed the manuscript, SC performed experiments and reviewed the manuscript, AGMTP performed experiments and analyzed the data, DCM helped developed the concept and revised the manuscript; PGH helped developed the concept and reviewed the manuscript; and JE developed the concept, designed the experiments and revised the manuscript.

REFERENCES

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur J Cancer* 2013; **49**: 1374-403.
2. Oliphant R, Nicholson GA, Horgan PG, Molloy RG, McMillan DC, Morrison DS, et al. Deprivation and colorectal cancer surgery: longer-term survival inequalities are due to differential postoperative mortality between socioeconomic groups. *Ann Surg Oncol* 2013; **20**: 2132-9.
3. van Brummelen EMJ, de Boer A, Beijnen JH, Schellens JHM BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies. *Oncologist* 2017; **22**: 864-872.
4. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. *J Natl Cancer Inst* 2013; **105**: 1151-6.
5. Dhillon AS, Hagan S, Rath O, Kolch W MAP kinase signalling pathways in cancer. *Oncogene* 2007; **26**: 3279-90.
6. Burotto M, Chiou VL, Lee JM, Kohn EC The MAPK pathway across different malignancies: a new perspective. *Cancer* 2014; **120**: 3446-56.

7. Yamamoto T, Ebisuya M, Ashida F, Okamoto K, Yonehara S, Nishida E Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression. *Curr Biol* 2006; **16**: 1171-82.
8. Fang JY, Richardson BC The MAPK signalling pathways and colorectal cancer. *Lancet Oncol* 2005; **6**: 322-7.
9. Fleming ID, American Joint Committee on Cancer., American Cancer Society., American College of Surgeons. (1997) AJCC cancer staging manual, 5th ed / Place. Lippincott-Raven: Philadelphia
10. Quirke P, Morris E Reporting colorectal cancer. *Histopathology* 2007; **50**: 103-12.
11. Park JH, Powell AG, Roxburgh CS, Horgan PG, McMillan DC, Edwards J Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment. *Br J Cancer* 2016; **114**: 562-70.
12. Richards CH, Roxburgh CSD, Anderson JH, McKee RF, Foulis AK, Horgan PG, et al. Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer. *The British journal of surgery* 2011; **99**: n/a-n/a.
13. Richards CH, Roxburgh CS, Powell AG, Foulis AK, Horgan PG, McMillan DC The clinical utility of the local inflammatory response in colorectal cancer. *Eur J Cancer* 2014; **50**: 309-19.


14. Park JH, McMillan DC, Powell AG, Richards CH, Horgan PG, Edwards J, et al. Evaluation of a Tumor Microenvironment-Based Prognostic Score in Primary Operable Colorectal Cancer. *Clin Cancer Res* 2014;
15. Park JH, Watt DG, Roxburgh CS, Horgan PG, McMillan DC Colorectal Cancer, Systemic Inflammation, and Outcome: Staging the Tumor and Staging the Host. *Ann Surg* 2015;
16. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). *Br J Cancer* 2005; **93**: 387-91.
17. Mukherjee R, McGuinness DH, McCall P, Underwood MA, Seywright M, Orange C, et al. Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer. *Br J Cancer* 2011; **104**: 1920-8.
18. Tai C-J, Chang C-C, Jiang M-C, Yeh C-M, Su T-C, Wu P-R, et al. Clinical-pathological correlation of <i>K-Ras</i> mutation and ERK phosphorylation in colorectal cancer. *Polish Journal of Pathology* 2012; **63**: 93-100.
19. Schmitz KJ, Wohlschlaeger J, Alakus H, Bohr J, Stauder MA, Worm K, et al. Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations. *Virchows Archiv* 2007; **450**: 151-159.

20. Wagner EF, Nebreda ÁR Signal integration by JNK and p38 MAPK pathways in cancer development. 2009; **9**: 537.
21. Xiao YQ, Malcolm K, Worthen GS, Gardai S, Schiemann WP, Fadok VA, et al. Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-beta. *J Biol Chem* 2002; **277**: 14884-93.
22. Fan XJ, Wan XB, Fu XH, Wu PH, Chen DK, Wang PN, et al. Phosphorylated p38, a negative prognostic biomarker, complements TNM staging prognostication in colorectal cancer. *Tumour Biol* 2014; **35**: 10487-95.
23. Yang SY, Miah A, Sales KM, Fuller B, Seifalian AM, Winslet M Inhibition of the p38 MAPK pathway sensitises human colon cancer cells to 5-fluorouracil treatment. *Int J Oncol* 2011; **38**: 1695-702.
24. Gupta J, del Barco Barrantes I, Igea A, Sakellariou S, Pateras IS, Gorgoulis VG, et al. Dual function of p38alpha MAPK in colon cancer: suppression of colitis-associated tumor initiation but requirement for cancer cell survival. *Cancer Cell* 2014; **25**: 484-500.
25. Melling N, Kowitz CM, Simon R, Bokemeyer C, Terracciano L, Sauter G, et al. High Ki67 expression is an independent good prognostic marker in colorectal cancer. *J Clin Pathol* 2016; **69**: 209-14.
26. Li P, Xiao ZT, Braciak TA, Ou QJ, Chen G, Oduncu FS Association between Ki67 Index and Clinicopathological Features in Colorectal Cancer. *Oncol Res Treat* 2016; **39**: 696-702.

TITLES AND LEGENDS TO FIGURES


Figure 1. Combined nuclear pERK/p-p38 score stratifies CSS in BRAF mutant CRC patients (n=782). Kaplan Meier curves showing associations between (A) pERK or (B) the combined nuclear pERK/p-p38 score and CSS in BRAF WT and BRAF mutant patients with CRC.

Figure 2. Combined nuclear pERK/p-p38 score differentially stratifies BRAF mutant CRC patient survival in MMR competent and MMR deficient patients (n=165). Kaplan Meier curves showing association between the combined nuclear pERK/p-p38 score and CSS in BRAF mutant patients with (A) MMR competent or (B) MMR deficient CRC.

A


Number of patients at risk

Low	265 (0)	223 (10)	176 (24)	155 (35)	138 (51)	94 (91)
High	352 (0)	290 (21)	244 (42)	205 (65)	177 (86)	127 (135)




Number of patients at risk

Low	50 (0)	36 (4)	27 (7)	24 (7)	19 (12)	12 (18)
High	115 (0)	102 (3)	91 (4)	79 (10)	69 (17)	53 (32)

B


Number of patients at risk

Low	344 (0)	285 (14)	227 (30)	197 (45)	173 (68)	115 (122)
High	273 (0)	228 (17)	193 (36)	163 (55)	142 (69)	106 (104)




Number of patients at risk

Low	70 (0)	56 (4)	44 (7)	37 (7)	30 (13)	21 (21)
High	95 (0)	82 (3)	74 (4)	66 (10)	58 (16)	44 (29)



Number of patients
at risk

Low	57 (0)	44 (3)	35 (6)	28 (6)	22 (11)	14 (19)
High	82 (0)	70 (3)	63 (4)	55 (10)	50 (13)	39 (23)



Number of patients
at risk

Low	14 (0)	12 (1)	9 (1)	9 (1)	8 (2)	7 (2)
High	13 (0)	12 (0)	11 (0)	11 (0)	8 (3)	5 (6)

Table 1. Phosphorylation of MAPK and cancer-specific survival in discovery cohort patients undergoing potentially curative resection of colorectal cancer (n=187)

	Nuclear			Cytoplasmic		
	<i>N</i> (%)	10yr CSS (SE)	<i>P</i>	<i>N</i> (%)	10yr CSS (SE)	<i>P</i>
pERK1/2						
Weak activation	71 (38)	55 (7)	0.048*	69 (37)	55 (7)	0.058
Strong activation	116 (62)	69 (5)		118 (63)	69 (5)	
p-p38MAPK						
Weak activation	67 (36)	58 (6)	0.237	143 (76)	64 (4)	0.985
Strong activation	120 (64)	67 (5)		44 (24)	61 (8)	
pJNK						
Weak activation	86 (46)	62 (6)	0.644	65 (35)	75 (6)	0.055
Strong activation	101 (54)	65 (5)		122 (65)	58 (5)	
Combined pERK/p-p38 score						
Both weak or one strong	110 (59)	57 (5)	0.03*	161 (86)	62 (4)	0.214
Both strong	77 (41)	73 (5)		26 (14)	75 (9)	
Combined pERK/pJNK score						
Both weak or one strong	129 (69)	61 (5)	0.217	112 (55)	66 (5)	0.67
Both strong	58 (31)	70 (6)		75 (45)	61 (6)	
Combined p-p38/pJNK score						
Both weak or one strong	121 (65)	60 (5)	0.245	156 (83)	64 (4)	0.724
Both strong	66 (35)	69 (6)		31 (17)	64 (9)	
* Significant difference $p < 0.05$						

Table 2. Phosphorylation of MAPK and cancer-specific survival in validation cohort patients undergoing potentially curative resection of colorectal cancer (n=801)

	Nuclear			Cytoplasmic		
	<i>N</i> (%)	10yr CSS (SE)	<i>P</i>	<i>N</i> (%)	10yr CSS (SE)	<i>P</i>
pERK1/2						
Weak activation	327 (41)	64 (3)		379 (47)	65 (3)	0.047*
Strong activation	474 (59)	72 (2)	0.037*	422 (53)	72 (2)	
p-p38MAPK						
Weak activation	251 (31)	65 (3)	0.236	380 (47)	66 (3)	0.268
Strong activation	550 (69)	70 (2)		421 (53)	71 (2)	
Combined pERK/p-p38 score						
Both weak or one strong	427 (53)	64 (2)	0.005*	536 (67)	65 (2)	0.01*
Both strong	374 (47)	74 (2)		265 (33)	76 (3)	

* Significant difference $p < 0.05$

Table 3. Clinicopathological characteristics of validation patients undergoing potentially curative resection of colorectal cancer and cancer-s survival (n=801)

	Nuclear pERK1/2			Cytoplasmic pERK1/2			Combined nuclear pERK/p38 score			Combined cytoplasmic pERK	
	Weak (n=327)	Strong (n=474)	P	Weak (n=379)	Strong (n=422)	P	Bothweak/one strong (n=427)	Both strong (n=374)	P	Both weak/one strong (n=536)	Both strong (n=265)
BRAF status											
Wild type	265 (84)	352 (75)	0.003*	306 (83)	331 (75)	0.009*	344 (83)	273 (74)	0.002*	416 (80)	201 (76)
Mutant	50 (16)	115 (25)		63 (17)	102 (25)		70 (17)	95 (26)		103 (20)	62 (24)
Mismatch repair status											
Competent	529 (80)	405 (86)	0.01*	302 (81)	362 (86)	0.032*	343 (81)	321 (86)	0.065	439 (83)	225 (85)
Deficient	66 (20)	63 (14)		72 (19)	57 (14)		78 (19)	51 (14)		89 (17)	40 (15)
Age											
<65	108 (33)	148 (31)	0.591	125 (33)	131 (31)	0.557	140 (33)	116 (31)	0.592	184 (34)	72 (27)
>65	219 (67)	326 (69)		254 (67)	291 (69)		287 (67)	258 (69)		352 (66)	193 (73)
Serum CRP											
Normal	137 (51)	222 (59)	0.03*	165 (55)	194 (57)	0.595	191 (53)	168 (59)	0.172	256 (56)	103 (54)
High	133 (49)	152 (41)		137 (45)	148 (43)		167 (47)	118 (41)		197 (44)	88 (46)
mGPS											
0	138 (51)	224 (59)	0.069	168 (55)	194 (57)	0.776	192 (53)	170 (59)	0.243	259 (57)	103 (54)
1	89 (33)	97 (26)		95 (31)	91 (26)		112 (31)	74 (26)		135 (29)	51 (27)
2	45 (16)	55 (15)		42 (14)	58 (17)		57 (16)	43 (15)		63 (14)	37 (19)
Tumour-infiltrating lymphocytes											
Absent	242 (76)	368 (79)	0.297	293 (79)	317 (77)	0.527	313 (76)	297 (81)	0.061	398 (76)	212 (82)
Present	75 (24)	95 (21)		77 (21)	93 (23)		101 (24)	69 (19)		123 (24)	47 (18)
Klintrup-Makinen grade											
Weak	217 (68)	317 (68)	0.966	257 (69)	277 (67)	0.514	276 (66)	258 (70)	0.31	362 (69)	172 (66)
Strong	102 (32)	150 (32)		115 (31)	137 (33)		140 (34)	112 (30)		164 (31)	88 (34)
TNM-stage											
1	45 (14)	65 (14)	0.567	51 (14)	59 (14)	0.152	61 (14)	49 (13)	0.996	68 (13)	42 (16)
2	152 (46)	234 (49)		171 (45)	215 (51)		201 (47)	185 (50)		252 (47)	134 (51)
3	130 (40)	175 (37)		157 (41)	148 (35)		165 (39)	140 (37)		216 (40)	89 (33)
Venous invasion											
Absent	218 (67)	318 (67)	0.901	254 (67)	282 (67)	0.954	281 (66)	255 (68)	0.476	353 (66)	183 (69)
Present	109 (33)	156 (33)		125 (33)	140 (33)		146 (34)	119 (32)		183 (34)	82 (31)
Proliferation Index											
Low	146 (45)	213 (45)	0.943	169 (45)	190 (46)	0.835	197 (47)	162 (44)	0.412	235 (44)	124 (47)
High	178 (55)	259 (55)		208 (55)	227 (54)		226 (53)	209 (56)		295 (56)	140 (53)

* Significant difference p<0.05

specific
/p38 score
<i>P</i>
0.228
0.526
0.039*
0.547
0.192
0.078
0.451
0.052
0.364
0.483

Table 4. Multivariate analysis of MAPK phosphorylation, clinicopathological characteristics and cancer specific survival in patients with colorectal cancer (n=606)

	Multivariate HR (95% CI)	P
All Patients (n=606)		
TNM Stage (I/II/III)	1.87 (1.44-2.45)	<0.001
Differentiation (Moderate or well/Poor)	1.10 (0.69-1.75)	0.703
Venous invasion (absent/present)	1.53 (1.13-2.07)	0.006
Margin Involvement (no/yes)	1.69 (1.05-2.73)	0.032
Peritoneal involvement (no/yes)	1.79 (1.31-2.45)	<0.001
Proliferation Index (Low/High)	0.81 (0.60-1.10)	0.178
Tumour stroma percentage (low/high)	1.43 (1.04-1.99)	0.030
Klintrup-Makinen Grade (weak/strong)	0.64 (0.48-0.88)	0.030
TILs (absent/present)	0.48 (0.30-0.77)	0.002
mGPS (0/1/2)	1.57 (1.30-1.91)	<0.001
Nuclear pERK (low/high)	0.65 (0.48-0.88)	0.004
Combined nuclear pERK/p-p38 score (both low or one high/both high)	0.61 (0.45-0.82)	0.001
MMR competent BRAF mutant patients (n=136)		
TNM Stage (I/II/III)	1.32 (0.74-2.38)	0.351
Venous invasion (absent/present)	2.58 (1.37-4.86)	0.003
Margin Involvement (no/yes)	4.45 (1.45-13.70)	0.009
Peritoneal involvement (no/yes)	0.95 (0.48-1.89)	0.887
Klintrup-Makinen Grade (weak/strong)	0.72 (0.31-1.65)	0.436
TILs (absent/present)	0.42 (0.17-1.02)	0.054
mGPS (0/1/2)	2.66 (1.78-3.98)	<0.001
Nuclear pERK (low/high)	0.52 (0.28-0.98)	0.042
Combined nuclear pERK/p-p38 score (both low or one high/both high)	0.58 (0.31-1.06)	0.077
Stage III MMR competent BRAF mutant patients (n=53)		
Venous invasion (absent/present)	1.17 (0.43-3.15)	0.762
Margin Involvement (no/yes)	6.59 (1.21-35.87)	0.029
Klintrup-Makinen Grade (weak/strong)	0.19 (0.02-1.44)	0.107
TILs (absent/present)	0.21 (0.03-1.69)	0.143
mGPS (0/1/2)	3.01 (1.58-5.73)	0.001
Nuclear pERK (low/high)	0.16 (0.06-0.44)	<0.001
Combined nuclear pERK/p-p38 score (both low or one high/both high)	0.34 (0.10-1.19)	0.091
* Significant difference		